Efficacy and safety of Menatetrenone-4 postmenopausal Thai women.
Clinical and comparative study of the efficacy and adverse events of Menatetrenone-4. The control group (n=40) received elemental calcium carbonate 800 mg/day and the Menatetrenone-4 treated group received elemental calcium carbonate 800 mg/day plus vitamin K2 45 mg/day (n=43). The vitamin K2 treated group showed a marked decrease of undercarboxylated osteocalcin at 2 weeks, six months (51.52% p=0.0001) and twelve months (87.26% p=0.0001) compared to the calcium treated group. At the end of the sixth and twelve months both groups did not increase bone mass of the hip but the vitamin K2 treated group increased 0.6 per cent of bone mass of the lumbar spine and decreased bone resorption 65.42 per cent (p=0.0001) compared to the calcium treated group. The calcium treated group was switched to the vitamin K2 treated group at the end of six months and showed a decrease of the level of undercarboxylated osteocalcin the same as the former vitamin K2 treated group. The adverse events were 2 cases of mild skin rash which subsided after cessation of medication.
Bunyaratavej
N
N
Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Penkitti
P
P
Kittimanon
N
N
Boonsangsom
P
P
Bonjongsat
A
A
Yunoi
S
S
D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000517:prevention & control*; D002119:Calcium Carbonate / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015675:Osteocalcin / Q000097:blood; D017698:Postmenopause; D024482:Vitamin K 2 / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D015675:Osteocalcin; D024482:Vitamin K 2; C030814:menatetrenone; D002119:Calcium Carbonate